ArticleCancers2022

Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer.

Koichiro Nakajima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.